TRICENTO G2 Valve for Severe Tricuspid Regurgitation
Part of Heart & circulation clinical trials.
This trial tests a new catheter-based valve (TRICENTO G2) designed to treat severe tricuspid regurgitation—a condition where blood leaks backward through the tricuspid valve in your heart. Instead of open-heart surgery, doctors thread the valve through blood vessels to repair the problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe tricuspid regurgitation (leaking tricuspid valve) confirmed by imaging
- You have symptoms of heart failure (shortness of breath, fatigue) or are in NYHA class II–IV
- Your heart's anatomy is suitable for this valve based on CT, ultrasound, or catheterization
- You are on optimal medical treatment for your heart condition
- You can commit to follow-up visits and agree to participate
- You have no recent heart attacks, other valve surgery plans, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, less invasive valve device (TricValve) for people with severe tricuspid regurgitation who are not good candidates for open-heart surgery. It aims to see if this device can help your heart pump better and improve your symptoms.
This trial looks at a catheter-based procedure using the TricValve system for people with severe “tricuspid regurgitation” (a leaky tricuspid valve) who are very symptomatic. It may help reduce the backflow and improve heart function, especially for people who are too unwell for or not helped by standard options.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This trial tests whether a new minimally invasive valve replacement device (put through a catheter) can improve health in people with severe right-sided tricuspid valve leaking. It’s for patients who are considered too high-risk for standard open-heart tricuspid surgery.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a new device, called the Laplace TTVR System, to replace the tricuspid valve in people whose leaky valve (tricuspid regurgitation) continues to cause symptoms despite medical treatment. It may help if you have severe symptoms and are not a candidate for open-heart surgery.
Hear when a new Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.